BioTime to Host Investor and Analyst Day on

to Host Investor and Analyst Day on December 15, 2014

ALAMEDA, Calif.--(BUSINESS WIRE)--December 12, 2014--BioTime, Inc. (NYSE

MKT: BTX), a biotechnology company that develops and markets products in

the field of regenerative medicine, announced today that it will host

its Investor and Analyst Day meeting on Monday, December 15, 2014 at

the Harvard Club of New York City. A live webcast of the presentations

will begin at 1:15 pm ET and the webcast will conclude by 4:00 pm ET.

Presentations will provide an overview of BioTime's growth opportunities

and operational strategy. Speakers include BioTime Chief Executive

Officer and President Michael D. West, PhD, Asterias Biotherapeutics

Chief Operating Officer Katharine Spink, PhD, and other members of the

executive management team of BioTime and its subsidiaries.

Advanced registration is required, and attendance will be limited to

institutional investors and equity research analysts who register in

advance. To register for the meeting, please contact BioTime's Investor

Relations: Michael Polyviou of EVC Group, Inc. at mpolyviou@evcgroup.com.

Investors and other interested parties unable to attend in person are

invited to listen to the investor meeting via a live webcast at: http://wsw.com/webcast/cc/btx.

A replay of the event will be available at the same website for 90 days

following the conclusion of the meeting.

BioTime is a biotechnology company engaged in research and product

development in the field of regenerative medicine. Regenerative medicine

refers to therapies based on stem cell technology that are designed to

rebuild cell and tissue function lost due to degenerative disease or

injury. BioTime's focus is on pluripotent stem cell technology based on

human embryonic stem ("hES") cells and induced pluripotent stem ("iPS")

cells. hES and iPS cells provide a means of manufacturing every cell

type in the human body and therefore show considerable promise for the

development of a number of new therapeutic products. BioTime's

therapeutic and research products include a wide array of proprietary PureStem

progenitors, HyStem hydrogels, culture media,

and differentiation kits. Renevia (a HyStem

product), is now in a pivotal trial in Europe as a biocompatible,

implantable hyaluronan and collagen-based matrix for cell delivery in

the treatment of HIV-related lipoatrophy. In addition, BioTime has

developed Hextend , a blood plasma volume

expander for use in surgery, emergency trauma treatment and other

applications. Hextend is manufactured and

distributed in the U.S. by Hospira, Inc. and in South Korea by CJ

HealthCare Corporation, under exclusive licensing agreements.

BioTime is also developing stem cell and other products for research,

therapeutic, and diagnostic use through its subsidiaries:

Asterias Biotherapeutics, Inc. is developing pluripotent stem-cell

based therapies in neurology and oncology, including AST-OPC1

oligodendrocyte progenitor cells in spinal cord injury, multiple

sclerosis and stroke, and AST-VAC2, an allogeneic dendritic cell-based

cancer vaccine. Asterias Series A common stock is traded on the NYSE

MKT under the symbol AST.

BioTime Asia, Ltd., a Hong Kong company, may offer and sell products

for research use for BioTime's ESI BIO Division.

Cell Cure Neurosciences Ltd. is an Israel-based biotechnology company

focused on developing stem cell-based therapies for retinal and

neurological disorders. OpRegen is currently in a Phase I/IIa

clinical trial for the treatment of the dry-form of age-related

macular degeneration.

ESI BIO is the research and product marketing division of BioTime,

providing stem cell researchers with products and technologies to

enable them to translate their work into the clinic, including PureStem

progenitors and HyStem hydrogels.

LifeMap Sciences, Inc. markets, sells, and distributes GeneCards ,

the leading human gene database, as part of an integrated database

suite that also includes the LifeMap Discovery

database of embryonic development, stem cell research, and

regenerative medicine, and MalaCards, the human disease

LifeMap Solutions, Inc. is a subsidiary of LifeMap Sciences focused on

developing mobile health (mHealth) products.

OncoCyte Corporation is developing products and technologies to

diagnose and treat cancer, including PanC-Dx , with four

clinical studies currently underway.

OrthoCyte Corporation is developing therapies to treat orthopedic

disorders, diseases and injuries.

ReCyte Therapeutics, Inc. is developing therapies to treat a variety

of cardiovascular and related ischemic disorders, as well as products

for research using cell reprogramming technology.

BioTime common stock is traded on the NYSE MKT under the symbol BTX. For

more information, please visit www.biotimeinc.com or

connect with the company on Twitter, LinkedIn, Facebook, YouTube, and

Forward-Looking Statements

Statements pertaining to future financial and/or operating results,

future growth in research, technology, clinical development, and

potential opportunities for BioTime and its subsidiaries, along with

other statements about the future expectations, beliefs, goals, plans,

or prospects expressed by management constitute forward-looking

statements. Any statements that are not historical fact (including, but

not limited to statements that contain words such as "will," "believes,"

"plans," "anticipates," "expects," "estimates") should also be

considered to be forward-looking statements. Forward-looking statements

involve risks and uncertainties, including, without limitation, risks

inherent in the development and/or commercialization of potential

products, uncertainty in the results of clinical trials or regulatory

approvals, need and ability to obtain future capital, and maintenance of

intellectual property rights. Actual results may differ materially from

the results anticipated in these forward-looking statements and as such

should be evaluated together with the many uncertainties that affect the

business of BioTime and its subsidiaries, particularly those mentioned

in the cautionary statements found in BioTime's Securities and Exchange

Commission filings. BioTime disclaims any intent or obligation to update

these forward-looking statements.

To receive ongoing BioTime corporate communications, please click on the